Clinical trial
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With…
NCT03713593 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT03713593 |
|---|---|
| Title | Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) |
| Official title | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma (LEAP-002) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Eisai Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Biological, Drug |
| Interventions | lenvatinib, pembrolizumab, saline placebo |
| Enrollment | 794 |
| Start date | Dec 31, 2018 |
| Primary completion | Jun 21, 2022 |
| Completion | Sep 24, 2024 |
| First posted | Oct 22, 2018 |
| Last update posted | Feb 5, 2026 |
| Countries | Australia, Canada, Chile, China, Colombia, France, Germany, Ireland, Italy, Japan, Mexico, New Zealand and 9 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: